Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Enveric Biosciences, Inc.

Enveric Biosciences Announces Closing of $5 Million Public Offering
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Pricing of $5 Million Public Offering
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Appoints New Independent Directors
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces $8 Million Registered Direct Offering and Private Placement, Priced at a Premium to Market Under Nasdaq Rules
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Reverse Stock Split
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio
From Enveric Biosciences, Inc.
Via Business Wire
Tickers ENVB
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.